PVLA · Palvella Therapeutics, Inc.

Palvella’s 8-K filing and accompanying press release highlights strong operational momentum as the company advances its lead QTORIN™ rapamycin candidate for rare skin and vascular malformations. Management noted positive Phase 3 SELVA trial results for QTORIN™ in microcystic lymphatic malformations announced in February 2026, supporting a planned New Drug Application submission in the second half of 2026, with potential first FDA approval in the first half of 2027. The company is accelerating U.S. launch readiness efforts for the candidate, which could become the first FDA-approved therapy for the estimated 30,000+ diagnosed U.S. microcystic LM patients. The $230 million oversubscribed equity financing completed in February 2026 strengthens the company’s balance sheet, with pro forma cash of approximately $274 million as of December 31, 2025 expected to fund operations through the QTORIN™ microcystic LM launch, NDA submission for the cutaneous venous malformations indication, and multiple Phase 2 trial readouts across its pipeline. Additional 2026 pipeline milestones include initiation of a Phase 2 trial for clinically significant angiokeratomas in Q2 2026, earlier than prior guidance, and a Phase 2 trial for QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis in H2 2026.